{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:47:41Z","timestamp":1793710061235,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA256464"],"award-info":[{"award-number":["R21CA256464"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prognosis of children with high-risk hepatoblastoma (HB), the most common pediatric liver cancer, remains poor. In this study, we found ribonucleotide reductase (RNR) subunit M2 (\n                    <jats:italic>RRM2<\/jats:italic>\n                    ) was one of the key genes supporting cell proliferation in high-risk HB. While standard chemotherapies could effectively suppress RRM2 in HB cells, they induced a significant upregulation of the other RNR M2 subunit, RRM2B. Computational analysis revealed distinct signaling networks RRM2 and RRM2B were involved in HB patient tumors, with RRM2 supporting cell proliferation and RRM2B participating heavily in stress response pathways. Indeed, RRM2B upregulation in chemotherapy-treated HB cells promoted cell survival and subsequent relapse, during which RRM2B was gradually replaced back by RRM2. Combining an RRM2 inhibitor with chemotherapy showed an effective delaying of HB tumor relapse in vivo. Overall, our study revealed the distinct roles of the two RNR M2 subunits and their dynamic switching during HB cell proliferation and stress response.\n                  <\/jats:p>","DOI":"10.1038\/s42003-023-04630-7","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T23:32:29Z","timestamp":1678231949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4408-3998","authenticated-orcid":false,"given":"Anthony","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8974-6551","authenticated-orcid":false,"given":"Emilie","family":"Indersie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Timchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2299-650X","authenticated-orcid":false,"given":"Baranda S.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-7648","authenticated-orcid":false,"given":"Junmin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-585X","authenticated-orcid":false,"given":"Shondra M.","family":"Pruett-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3629-4330","authenticated-orcid":false,"given":"Jiyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-5970","authenticated-orcid":false,"given":"Stefano","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-150X","authenticated-orcid":false,"given":"Liqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"4630_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/hpb.12112","volume":"15","author":"BJ Allan","year":"2013","unstructured":"Allan, B. J. et al. Predictors of survival and incidence of hepatoblastoma in the paediatric population. Hpb 15, 741\u2013746 (2013).","journal-title":"Hpb"},{"key":"4630_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1634\/theoncologist.2008-0011","volume":"13","author":"JB Litten","year":"2008","unstructured":"Litten, J. B. & Tomlinson, G. E. Liver tumors in children. Oncologist 13, 812\u2013820 (2008).","journal-title":"Oncologist"},{"key":"4630_CR3","doi-asserted-by":"publisher","first-page":"pkz007","DOI":"10.1093\/jncics\/pkz007","volume":"3","author":"AK Hubbard","year":"2019","unstructured":"Hubbard, A. K., Spector, L. G., Fortuna, G., Marcotte, E. L. & Poynter, J. N. Trends in international incidence of pediatric cancers in children under 5 years of age: 1988\u20132012. JNCI Cancer Spectr 3, pkz007 (2019).","journal-title":"JNCI Cancer Spectr"},{"key":"4630_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","volume":"18","author":"RL Meyers","year":"2017","unstructured":"Meyers, R. L. et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration. Lancet Oncol. 18, 122\u2013131 (2017).","journal-title":"Lancet Oncol."},{"key":"4630_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41416-019-0648-6","volume":"122","author":"CC Bell","year":"2019","unstructured":"Bell, C. C. & Gilan, O. Principles and mechanisms of non-genetic resistance in cancer. Br. J. Cancer 122, 465\u2013472 (2019).","journal-title":"Br. J. Cancer"},{"key":"4630_CR6","doi-asserted-by":"crossref","unstructured":"Craig, A. J., von Felden, J., Garcia-Lezana, T., Sarcognato, S. & Villanueva, A. Tumour evolution in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 17, 139\u2013152 (2020).","DOI":"10.1038\/s41575-019-0229-4"},{"key":"4630_CR7","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1158\/2159-8290.CD-20-1809","volume":"11","author":"TZ Hirsch","year":"2021","unstructured":"Hirsch, T. Z. et al. Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer. Cancer Discov. 11, 2524\u20132543 (2021).","journal-title":"Cancer Discov."},{"key":"4630_CR8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ajpath.2017.11.013","volume":"188","author":"L Li","year":"2018","unstructured":"Li, L. et al. Acquisition of cholangiocarcinoma traits during advanced hepatocellular carcinoma development in mice. Am. J. Pathol. 188, 656\u2013671 (2018).","journal-title":"Am. J. Pathol."},{"key":"4630_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-biochem-013118-111843","volume":"89","author":"BL Greene","year":"2020","unstructured":"Greene, B. L. et al. Ribonucleotide reductases: structure, chemistry, and metabolism suggest new therapeutic targets. Annu. Rev. Biochem. 89, 45\u201375 (2020).","journal-title":"Annu. Rev. Biochem."},{"key":"4630_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0968-0004(92)90249-9","volume":"17","author":"SJ Elledge","year":"1992","unstructured":"Elledge, S. J., Zhou, Z. & Allen, J. B. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem. Sci. 17, 119\u2013123 (1992).","journal-title":"Trends Biochem. Sci."},{"key":"4630_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1365-2958.2006.05493.x","volume":"63","author":"J Herrick","year":"2007","unstructured":"Herrick, J. & Sclavi, B. Ribonucleotide reductase and the regulation of DNA replication: an old story and an ancient heritage. Mol. Microbiol. 63, 22\u201334 (2007).","journal-title":"Mol. Microbiol."},{"key":"4630_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbrc.2005.12.019","volume":"340","author":"W Qiu","year":"2006","unstructured":"Qiu, W., Zhou, B., Darwish, D., Shao, J. & Yen, Y. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits. Biochem. Biophys. Res. Commun. 340, 428\u2013434 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"4630_CR13","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/onc.2014.155","volume":"34","author":"Y Aye","year":"2015","unstructured":"Aye, Y., Li, M., Long, M. J. & Weiss, R. S. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene 34, 2011\u20132021 (2015).","journal-title":"Oncogene"},{"key":"4630_CR14","doi-asserted-by":"publisher","first-page":"110996","DOI":"10.1016\/j.biopha.2020.110996","volume":"133","author":"Y Zhan","year":"2021","unstructured":"Zhan, Y. et al. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomed. Pharmacother 133, 110996 (2021).","journal-title":"Biomed. Pharmacother"},{"key":"4630_CR15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.5009\/gnl13392","volume":"8","author":"B Lee","year":"2014","unstructured":"Lee, B. et al. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma. Gut Liver 8, 662\u2013668 (2014).","journal-title":"Gut Liver"},{"key":"4630_CR16","doi-asserted-by":"publisher","first-page":"9927","DOI":"10.2147\/OTT.S221339","volume":"12","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. RRM2 regulated by LINC00667\/miR-143-3p signal is responsible for non-small cell lung cancer cell progression. Onco. Targets Ther. 12, 9927\u20139939 (2019).","journal-title":"Onco. Targets Ther."},{"key":"4630_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3892\/mmr.2015.3360","volume":"12","author":"P Han","year":"2015","unstructured":"Han, P. et al. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma. Mol. Med. Rep. 12, 401\u2013409 (2015).","journal-title":"Mol. Med. Rep."},{"key":"4630_CR18","first-page":"2535","volume":"31","author":"Y Yoshida","year":"2011","unstructured":"Yoshida, Y. et al. KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res. 31, 2535\u20132539 (2011).","journal-title":"Anticancer Res."},{"key":"4630_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7150\/ijbs.30114","volume":"15","author":"H Sun","year":"2019","unstructured":"Sun, H. et al. RRM2 is a potential prognostic biomarker with functional significance in glioma. Int. J. Biol. Sci. 15, 533\u2013543 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"4630_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biochi.2016.01.008","volume":"123","author":"EC Cho","year":"2016","unstructured":"Cho, E. C. & Yen, Y. Novel regulators and molecular mechanisms of p53R2 and its disease relevance. Biochimie 123, 81\u201384 (2016).","journal-title":"Biochimie"},{"key":"4630_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.molcel.2017.03.005","volume":"66","author":"IP Foskolou","year":"2017","unstructured":"Foskolou, I. P. et al. Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication. Mol. Cell 66, 206\u2013220 e209 (2017).","journal-title":"Mol. Cell"},{"key":"4630_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1535-7163.MCT-10-0728","volume":"10","author":"K Zhang","year":"2011","unstructured":"Zhang, K. et al. p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest. Mol. Cancer Ther. 10, 269\u2013278 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"4630_CR23","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.cell.2016.07.045","volume":"166","author":"L Zhu","year":"2016","unstructured":"Zhu, L. et al. Multi-organ mapping of cancer risk. Cell 166, 1132\u20131146 e1137 (2016).","journal-title":"Cell"},{"key":"4630_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/hep.28888","volume":"65","author":"P Sumazin","year":"2017","unstructured":"Sumazin, P. et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology 65, 104\u2013121 (2017).","journal-title":"Hepatology"},{"key":"4630_CR25","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"Cancer Genome Atlas Research Network.","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Electronic address, w.b.e. & cancer genome atlas research, N. comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327\u20131341 e1323 (2017).","journal-title":"Cell"},{"key":"4630_CR26","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","volume":"40","author":"D Lopez-Terrada","year":"2009","unstructured":"Lopez-Terrada, D., Cheung, S. W., Finegold, M. J. & Knowles, B. B. Hep G2 is a hepatoblastoma-derived cell line. Hum. Pathol. 40, 1512\u20131515 (2009).","journal-title":"Hum. Pathol."},{"key":"4630_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17665-8","volume":"7","author":"SE Woodfield","year":"2017","unstructured":"Woodfield, S. E. et al. A novel cell line based orthotopic xenograft mouse model that recapitulates human hepatoblastoma. Sci. Rep. 7, 17751 (2017).","journal-title":"Sci. Rep."},{"key":"4630_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0065-2571(98)00017-X","volume":"39","author":"RA Finch","year":"1999","unstructured":"Finch, R. A., Liu, M. C., Cory, A. H., Cory, J. G. & Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul. 39, 3\u201312 (1999).","journal-title":"Adv. Enzyme Regul."},{"key":"4630_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","volume":"28","author":"SX Pfister","year":"2015","unstructured":"Pfister, S. X. et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell 28, 557\u2013568 (2015).","journal-title":"Cancer Cell"},{"key":"4630_CR30","doi-asserted-by":"publisher","first-page":"104398","DOI":"10.1016\/j.phrs.2019.104398","volume":"148","author":"C Bailly","year":"2019","unstructured":"Bailly, C. Irinotecan: 25 years of cancer treatment. Pharmacol. Res. 148, 104398 (2019).","journal-title":"Pharmacol. Res."},{"key":"4630_CR31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/hep.28621","volume":"64","author":"D Nicolle","year":"2016","unstructured":"Nicolle, D. et al. Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management. Hepatology 64, 1121\u20131135 (2016).","journal-title":"Hepatology"},{"key":"4630_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.32412","volume":"76","author":"L Fan","year":"2022","unstructured":"Fan, L. et al. A developmentally prometastatic niche to hepatoblastoma in neonatal liver mediated by the Cxcl1\/Cxcr2 axis. Hepatology 76, 1275\u20131290 (2022).","journal-title":"Hepatology"},{"key":"4630_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lfs.2014.01.063","volume":"99","author":"B Yousefi","year":"2014","unstructured":"Yousefi, B., Rahmati, M. & Ahmadi, Y. The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. Life Sci. 99, 14\u201317 (2014).","journal-title":"Life Sci."},{"key":"4630_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3350\/cmh.2015.21.3.230","volume":"21","author":"YR Lee","year":"2015","unstructured":"Lee, Y. R. & Park, S. Y. P53 expression in hepatocellular carcinoma: influence on the radiotherapeutic response of the hepatocellular carcinoma. Clin. Mol. Hepatol. 21, 230\u2013231 (2015).","journal-title":"Clin. Mol. Hepatol."},{"key":"4630_CR35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/carcin\/14.5.987","volume":"14","author":"IC Hsu","year":"1993","unstructured":"Hsu, I. C. et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14, 987\u2013992 (1993).","journal-title":"Carcinogenesis"},{"key":"4630_CR36","doi-asserted-by":"publisher","first-page":"8730816","DOI":"10.1155\/2019\/8730816","volume":"2019","author":"F Ciccarese","year":"2019","unstructured":"Ciccarese, F., Zulato, E. & Indraccolo, S. LKB1\/AMPK pathway and drug response in cancer: a therapeutic perspective. Oxid. Med. Cell Longev. 2019, 8730816 (2019).","journal-title":"Oxid. Med. Cell Longev."},{"key":"4630_CR37","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2174\/0929867033457638","volume":"10","author":"JL Buss","year":"2003","unstructured":"Buss, J. L., Torti, F. M. & Torti, S. V. The role of iron chelation in cancer therapy. Curr. Med. Chem. 10, 1021\u20131034 (2003).","journal-title":"Curr. Med. Chem."},{"key":"4630_CR38","doi-asserted-by":"publisher","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","volume":"203","author":"MH Jin","year":"2019","unstructured":"Jin, M. H. & Oh, D. Y. ATM in DNA repair in cancer. Pharmacol. Ther. 203, 107391 (2019).","journal-title":"Pharmacol. Ther."},{"key":"4630_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/35003506","volume":"404","author":"H Tanaka","year":"2000","unstructured":"Tanaka, H. et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404, 42\u201349 (2000).","journal-title":"Nature"},{"key":"4630_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.gene.2017.11.008","volume":"642","author":"A Azimi","year":"2018","unstructured":"Azimi, A. et al. Suppression of p53R2 gene expression with specific siRNA sensitizes HepG2 cells to doxorubicin. Gene 642, 249\u2013255 (2018).","journal-title":"Gene"},{"key":"4630_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.07.019","volume":"276","author":"X Wang","year":"2009","unstructured":"Wang, X., Zhenchuk, A., Wiman, K. G. & Albertioni, F. Regulation of p53R2 and its role as potential target for cancer therapy. Cancer Lett. 276, 1\u20137 (2009).","journal-title":"Cancer Lett."},{"key":"4630_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321\u2013327 (2018).","journal-title":"Nature"},{"key":"4630_CR43","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature12624","volume":"501","author":"CE Meacham","year":"2013","unstructured":"Meacham, C. E. & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328\u2013337 (2013).","journal-title":"Nature"},{"key":"4630_CR44","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine, J. C., Dawson, S. J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743\u2013756 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"4630_CR45","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1053\/j.gastro.2014.05.004","volume":"147","author":"J Tao","year":"2014","unstructured":"Tao, J. et al. Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology 147, 690\u2013701 (2014).","journal-title":"Gastroenterology"},{"key":"4630_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3727\/105221616X693639","volume":"17","author":"D Bell","year":"2017","unstructured":"Bell, D., Ranganathan, S., Tao, J. & Monga, S. P. Novel advances in understanding of molecular pathogenesis of hepatoblastoma: a Wnt\/beta-catenin perspective. Gene Expr. 17, 141\u2013154 (2017).","journal-title":"Gene Expr."},{"key":"4630_CR47","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.18632\/oncotarget.27237","volume":"10","author":"D Kats","year":"2019","unstructured":"Kats, D. et al. Volasertib preclinical activity in high-risk hepatoblastoma. Oncotarget 10, 6403\u20136417 (2019).","journal-title":"Oncotarget"},{"key":"4630_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19441-8","volume":"8","author":"MF Sentmanat","year":"2018","unstructured":"Sentmanat, M. F., Peters, S. T., Florian, C. P., Connelly, J. P. & Pruett-Miller, S. M. A survey of validation strategies for CRISPR-Cas9 editing. Sci. Rep. 8, 888 (2018).","journal-title":"Sci. Rep."},{"key":"4630_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40896-w","volume":"9","author":"JP Connelly","year":"2019","unstructured":"Connelly, J. P. & Pruett-Miller, S. M. CRIS.py: a versatile and high-throughput analysis program for CRISPR-based genome editing. Sci. Rep. 9, 4194 (2019).","journal-title":"Sci. Rep."},{"key":"4630_CR50","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48, W488\u2013W493 (2020).","journal-title":"Nucleic Acids Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04630-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04630-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04630-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:03:14Z","timestamp":1678233794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04630-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4630"],"URL":"https:\/\/doi.org\/10.1038\/s42003-023-04630-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.24.525404","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"5 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"249"}}